News
Two-thirds of UK adults use Traditional Complementary and Integrative Medicine, national survey finds
20 January 2026Intel: Centrino Wireless-n 1030 Advanced-n 6230 Driver Windows 10
Intel’s Centrino branding represented a platform-level integration of Wi-Fi, chipset, and CPU. The Wireless-N 1030 and Advanced-N 6230 were mid-range adapters designed for Windows 7, featuring 1x1 and 2x2 antenna configurations respectively. With the release of Windows 10 in 2015, Microsoft’s new driver model (WDF 2.0) and deprecation of legacy NDIS 5.x protocols rendered many older drivers incompatible or unstable.
Legacy Hardware in a Modern OS: A Technical Review of the Intel Centrino Wireless-N 1030 and Advanced-N 6230 Drivers for Windows 10 Legacy Hardware in a Modern OS: A Technical
The 6230 shares a single antenna path between Wi-Fi and Bluetooth. On Windows 10, the coexistence protocol fails, causing Wi-Fi throughput to drop from 300 Mbps to <10 Mbps when any Bluetooth audio device is active. Mitigation: In driver advanced settings, set “Bluetooth AMP” to “Disabled” and “Wi-Fi/Bluetooth coexistence” to “Aggressive mode.” the coexistence protocol fails
| Feature | Intel Centrino Wireless-N 1030 | Intel Advanced-N 6230 | | :--- | :--- | :--- | | Form Factor | Half Mini PCIe | Half Mini PCIe | | Streams | 1x1 (150 Mbps max) | 2x2 (300 Mbps max) | | Frequency | 2.4 GHz only | 2.4 & 5 GHz (dual-band) | | Bluetooth | Integrated Bluetooth 3.0+HS | Integrated Bluetooth 4.0 | | Key Tech | Legacy 802.11b/g/n | Intel Wireless Display (WiDi) | Legacy Hardware in a Modern OS: A Technical
Hot off the press
A personalized, integrative approach in treating major depressive disorder: N-of-1 study with plasma proteome and physicochemical analysis of homeopathic preparations Open Access
Adler UC, Adler MS, dos Santos Nogueira R et al.
BBI Integrative. 2025; 11: 100133
Full text
Hear from the experts
News
HRI Statement on retraction of Frass et al. 2020 study which found benefits of ‘add-on’ homeopathy for cancer patients undergoing conventional cancer treatment
On 24 November, a clinical trial by Frass et al. 20201 assessing homeopathy provided in addition to usual oncology care in non-small-cell lung carcinoma patients, was retracted by the Editor of the journal. This study, using the gold-standard double-blind placebo-controlled trial design, found that patients receiving additional homeopathic treatment had improved quality of life and increased survival time, compared to the placebo group. More | DE
